|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J, Gores GJ and Mazzaferro V:
Hepatocellular carcinoma: Clinical frontiers and perspectives. Gut.
63:844–855. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prager BC, Xie Q, Bao S and Rich JN:
Cancer stem cells: The architects of the tumor ecosystem. Cell Stem
Cell. 24:41–53. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Najafi M, Farhood B and Mortezaee K:
Cancer stem cells (CSCs) in cancer progression and therapy. J Cell
Physiol. 234:8381–8395. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Xiang Y, Yang T, Pang BY, Zhu Y and Liu
YN: The progress and prospects of putative biomarkers for liver
cancer stem cells in hepatocellular carcinoma. Stem Cells Int.
2016:76149712016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang N, Wang S, Li MY, Hu BG, Liu LP, Yang
SL, Yang S, Gong Z, Lai PBS and Chen GG: Cancer stem cells in
hepatocellular carcinoma: An overview and promising therapeutic
strategies. Ther Adv Med Oncol. 10:17588359188162872018. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yamashita T, Honda M, Nakamoto Y, Baba M,
Nio K, Hara Y, Zeng SS, Hayashi T, Kondo M, Takatori H, et al:
Discrete nature of EpCAM+ and CD90+ cancer
stem cells in human hepatocellular carcinoma. Hepatology.
57:1484–1497. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Batista PJ and Chang HY: Long noncoding
RNAs: Cellular address codes in development and disease. Cell.
152:1298–1307. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sanchez Calle A, Kawamura Y, Yamamoto Y,
Takeshita F and Ochiya T: Emerging roles of long non-coding RNA in
cancer. Cancer Sci. 109:2093–2100. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang X, Hamblin MH and Yin KJ: The long
noncoding RNA Malat1: Its physiological and pathophysiological
functions. RNA Biol. 14:1705–1714. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Liu D, Zhu Y, Pang J, Weng X, Feng X and
Guo Y: Knockdown of long non-coding RNA MALAT1 inhibits growth and
motility of human hepatoma cells via modulation of miR-195. J Cell
Biochem. 119:1368–1380. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yuan P, Cao W, Zang Q, Li G, Guo X and Fan
J: The HIF-2α-MALAT1-miR-216b axis regulates multi-drug resistance
of hepatocellular carcinoma cells via modulating autophagy. Biochem
Biophys Res Commun. 478:1067–1073. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jiao F, Hu H, Han T, Yuan C and Wang L,
Jin Z, Guo Z and Wang L: Long noncoding RNA MALAT-1 enhances stem
cell-like phenotypes in pancreatic cancer cells. Int J Mol Sci.
16:6677–6693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Han Y, Zhou L, Wu T, Huang Y, Cheng Z, Li
X, Sun T, Zhou Y and Du Z: Downregulation of lncRNA-MALAT1 affects
proliferation and the expression of stemness markers in glioma stem
cell line SHG139S. Cell Mol Neurobiol. 36:1097–1107. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Akita H, Marquardt JU, Durkin ME, Kitade
M, Seo D, Conner EA, Andersen JB, Factor VM and Thorgeirsson SS:
MYC activates stem-like cell potential in hepatocarcinoma by a
p53-dependent mechanism. Cancer Res. 74:5903–5913. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Leis O, Eguiara A, Lopez-Arribillaga E,
Alberdi MJ, Hernandez-Garcia S, Elorriaga K, Pandiella A, Rezola R
and Martin AG: Sox2 expression in breast tumours and activation in
breast cancer stem cells. Oncogene. 31:1354–1365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kuo KK, Lee KT, Chen KK, Yang YH, Lin YC,
Tsai MH, Wuputra K, Lee YL, Ku CC, Miyoshi H, et al: Positive
feedback loop of OCT4 and c-JUN expedites cancer stemness in liver
cancer. Stem Cells. 34:2613–2624. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Fu H, Fu L, Xie C, Zuo WS, Liu YS, Zheng
MZ and Yu JM: miR-375 inhibits cancer stem cell phenotype and
tamoxifen resistance by degrading HOXB3 in human ER-positive breast
cancer. Oncol Rep. 37:1093–1099. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhu P, Wang Y, Wu J, Huang G, Liu B, Ye B,
Du Y, Gao G, Tian Y, He L, et al: LncBRM initiates YAP1 signalling
activation to drive self-renewal of liver cancer stem cells. Nat
Commun. 7:136082016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zanconato F, Cordenonsi M and Piccolo S:
YAP/TAZ at the Roots of Cancer. Cancer Cell. 29:783–803. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kandasamy S, Adhikary G, Rorke EA,
Friedberg JS, Mickle MB, Alexander HR and Eckert RL: The YAP1
signaling inhibitors, verteporfin and CA3, suppress the
mesothelioma cancer stem cell phenotype. Mol Cancer Res.
18:343–351. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Nio K, Yamashita T and Kaneko S: The
evolving concept of liver cancer stem cells. Mol Cancer. 16:42017.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li ZX, Zhu QN, Zhang HB, Hu Y, Wang G and
Zhu YS: MALAT1: A potential biomarker in cancer. Cancer Manag Res.
10:6757–6768. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoshimoto R, Mayeda A, Yoshida M and
Nakagawa S: MALAT1 long non-coding RNA in cancer. Biochim Biophys
Acta. 1859:192–199. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Konishi H, Ichikawa D, Yamamoto Y, Arita
T, Shoda K, Hiramoto H, Hamada J, Itoh H, Fujita Y, Komatsu S, et
al: Plasma level of metastasis-associated lung adenocarcinoma
transcript 1 is associated with liver damage and predicts
development of hepatocellular carcinoma. Cancer Sci. 107:149–154.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen Y, Huang W, Sun W, Zheng B, Wang C,
Luo Z, Wang J and Yan W: LncRNA MALAT1 promotes cancer metastasis
in osteosarcoma via activation of the PI3K-Akt signaling pathway.
Cell Physiol Biochem. 51:1313–1326. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ulitsky I and Bartel DP: lincRNAs:
Genomics, evolution, and mechanisms. Cell. 154:26–46. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kondo Y, Shinjo K and Katsushima K: Long
non-coding RNAs as an epigenetic regulator in human cancers. Cancer
Sci. 108:1927–1933. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tay Y, Rinn J and Pandolfi PP: The
multilayered complexity of ceRNA crosstalk and competition. Nature.
505:344–352. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang WT, Ye H, Wei PP, Han BW, He B, Chen
ZH and Chen YQ: LncRNAs H19 and HULC, activated by oxidative
stress, promote cell migration and invasion in cholangiocarcinoma
through a ceRNA manner. J Hematol Oncol. 9:1172016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan Y, Tong S, Cui R, Fan J, Liu C, Lin Y,
Tang J, Xie H, Lin P, Zheng T, et al: Long non-coding MALAT1
functions as a competing endogenous RNA to regulate vimentin
expression by sponging miR-30a-5p in hepatocellular carcinoma. Cell
Physiol Biochem. 50:108–120. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen L, Yao H, Wang K and Liu X: Long
non-coding RNA MALAT1 regulates ZEB1 expression by sponging
miR-143-3p and promotes hepatocellular carcinoma progression. J
Cell Biochem. 118:4836–4843. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li X: MiR-375, a microRNA related to
diabetes. Gene. 533:1–4. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yan JW, Lin JS and He XX: The emerging
role of miR-375 in cancer. Int J Cancer. 135:1011–1018. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhou N, Wu J, Wang X, Sun Z, Han Q and
Zhao L: Low-level expression of microRNA-375 predicts poor
prognosis in hepatocellular carcinoma. Tumour Biol. 37:2145–2152.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cao S, Wang G, Wang J, Li C and Zhang L:
Hsa_circ_101280 promotes hepatocellular carcinoma by regulating
miR-375/JAK2. Immunol Cell Biol. 97:218–228. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Li L, Jia L and Ding Y: Upregulation of
miR-375 inhibits human liver cancer cell growth by modulating cell
proliferation and apoptosis via targeting ErbB2. Oncol Lett.
16:3319–3326. 2018.PubMed/NCBI
|
|
39
|
He XX, Chang Y, Meng FY, Wang MY, Xie QH,
Tang F, Li PY, Song YH and Lin JS: MicroRNA-375 targets AEG-1 in
hepatocellular carcinoma and suppresses liver cancer cell growth in
vitro and in vivo. Oncogene. 31:3357–3369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chang Y, Yan W, He X, Zhang L, Li C, Huang
H, Nace G, Geller DA, Lin J and Tsung A: miR-375 inhibits autophagy
and reduces viability of hepatocellular carcinoma cells under
hypoxic conditions. Gastroenterology. 143:177–87.e8. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Zhao P, Wu S, Cheng Y, You J, Chen Y, Li
M, He C, Zhang X, Yang T, Lu Y, et al: MiR-375 delivered by
lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes
chemoresistance in hepatocellular carcinoma. Nanomedicine (Lond).
13:2507–2516. 2017. View Article : Google Scholar
|
|
42
|
Hansen CG, Moroishi T and Guan KL: YAP and
TAZ: A nexus for Hippo signaling and beyond. Trends Cell Biol.
25:499–513. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Shibata M, Ham K and Hoque MO: A time for
YAP1: Tumorigenesis, immunosuppression and targeted therapy. Int J
Cancer. 143:2133–2144. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Lu T, Li Z, Yang Y, Ji W, Yu Y, Niu X,
Zeng Q, Xia W and Lu S: The Hippo/YAP1 pathway interacts with FGFR1
signaling to maintain stemness in lung cancer. Cancer Lett.
423:36–46. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Bora-Singhal N, Nguyen J, Schaal C,
Perumal D, Singh S, Coppola D and Chellappan S: YAP1 regulates OCT4
activity and SOX2 expression to facilitate self-renewal and
vascular mimicry of stem-like cells. Stem Cells. 33:1705–1718.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Strnadel J, Choi S, Fujimura K, Wang H,
Zhang W, Wyse M, Wright T, Gross E, Peinado C, Park HW, et al:
eIF5A-PEAK1 signaling regulates YAP1/TAZ protein expression and
pancreatic cancer cell growth. Cancer Res. 77:1997–2007. 2017.
View Article : Google Scholar : PubMed/NCBI
|
